Anacor Pharmaceuticals(Anacor)’ lead compound, AN2690, is the first in a new class of antifungal agents that is being developed for onychomycosis, a fungal infection of the nail and nail bed.
The company recently announced that its Phase 1 trial of AN2690 showed that patients receiving the topical treatment had no measurable level of the drug in their bloodstream.
Read more at Anacor Pharmaceuticals."These new findings confirm preclinical toxicology work and showed that while the drug will concentrate at its target, the nail bed, it is not present at quantifiable levels in the bloodstream," said Dr. Karl Beutner, Anacor's chief medical officer.
"The level of drug found in the nail plate during AN2690 treatment was substantially higher than those found with currently available topical and oral agents."
.jpg)
Comment Preview